VRÁBLÍK, M., R. ČEŠKA, V. BLÁHA, T. FREIBERGER and Vladimír SOŠKA. Souhrn konsenzu panelu expertů European Atherosclerosis Society k otázce diagnostiky a klinickému vedení nemocných s homozygotní formou familiání hypercholesterolemie (A summary of the consensus of panel experts European Atherosclerosis Society to the diagnosis and clinical management of patients with homozygous familial hypercholesterolaemia). Hypertenze & kardiovaskulární prevence. Praha: Target MD, 2015, vol. 4, No 1, p. 54-56. ISSN 1805-4129.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Souhrn konsenzu panelu expertů European Atherosclerosis Society k otázce diagnostiky a klinickému vedení nemocných s homozygotní formou familiání hypercholesterolemie
Name (in English) A summary of the consensus of panel experts European Atherosclerosis Society to the diagnosis and clinical management of patients with homozygous familial hypercholesterolaemia
Authors VRÁBLÍK, M. (203 Czech Republic), R. ČEŠKA (203 Czech Republic), V. BLÁHA (203 Czech Republic), T. FREIBERGER (203 Czech Republic) and Vladimír SOŠKA (203 Czech Republic, guarantor, belonging to the institution).
Edition Hypertenze & kardiovaskulární prevence, Praha, Target MD, 2015, 1805-4129.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/15:00084616
Organization unit Faculty of Medicine
Keywords in English homozygous familial hypercholesterolemia; cardiovasular diseases; LDL-cholesterol; pharmacotherapy; LDL-aferesis
Tags EL OK
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 10/11/2015 15:15.
Abstract
Homozygotní forma familiární hypercholesterolemie je vzácné dědičné onemocnění charakterizované velmi vysokou koncentrací hladiny LDL cholesterolu a aterosklerotických komplikací v mladém věku. Léčba se obvykle skládá z kombinace vysokých dávek hypolipidemik a LDL-aferézou. V poslední době jsou k dispozici nové léky (inhibitory lomitapide a PCSK9).
Abstract (in English)
Homozygous familial hypercholesterolemia is a rare hereditary disease characterized by very high concentration of LDL-cholesterol levels and atherosclerotic complications in a young age. Treatment usually consists of combination of high doses hypolipidemic drugs and LDL-apheresis. Recently, new drugs (lomitapide and PCSK9 inhibitors) are available.
PrintDisplayed: 1/10/2024 13:55